IK-175, an oral AHR inhibitor, as monotherapy and in combination with nivolumab in patients with urothelial carcinoma resistant/refractory to PD-1/L1 inhibitors

被引：0
作者：
Aggen, David H.
McKean, Meredith
Hoffman-Censits, Jean H.
Lakhani, Nehal J.
Alhalabi, Omar
Guancial, Elizabeth A.
Bashir, Babar
Bowman, I. Alex
Tan, Alan
Lingaraj, Trupti
Kim, Katherine
Timothy, Marissa
Ortiz-Otero, Nerymar
Bartolini, Wilmin
Kacena, Katherine
Santillana, Sergio
Luke, Jason J.
机构：
[1] Mem Sloan Kettering Canc Ctr, Genitourinary Oncol, 1275 York Ave, New York, NY 10021 USA
[2] Weill Cornell Med Coll, New York, NY USA
[3] Sarah Cannon Res Inst, Nashville, TN USA
[4] Johns Hopkins, Johns Hopkins Greenberg Bladder Canc Inst, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[5] Johns Hopkins, Johns Hopkins Greenberg Bladder Canc Inst, Sidney Kimmel Comprehens Canc Ctr, Dept Urol, Baltimore, MD USA
[6] START Midwest, Grand Rapids, MI USA
[7] Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX 77030 USA
[8] Florida Canc Specialists & Res Inst, Sarasota, FL USA
[9] Thomas Jefferson Univ, Sarah Cannon Res Inst, Philadelphia, PA 19107 USA
[10] Thomas Jefferson Univ, Sidney Kimmel Canc Ctr, Philadelphia, PA 19107 USA
[11] Banner MD Anderson Canc Ctr, Gilbert, AZ USA
[12] Rush Univ, Med Ctr, Chicago, IL USA
[13] Ikena Oncol, Boston, MA USA
[14] UPMC Hillman Canc Ctr, Pittsburgh, PA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2599
引用
收藏
页数：1
相关论文
共 50 条
[41]   Enhanced programmed death 1 (PD-1) and PD-1 ligand (PD-L1) expression in patients with actinic cheilitis and oral squamous cell carcinoma [J].
de Souza Malaspina, Tatiana Salles ;
Gasparoto, Thais Helena ;
Sales Nogueira Costa, Maria Renata ;
de Melo, Edgard Franco, Jr. ;
Valerio Ikoma, Maura Rosane ;
Damante, Jose Humberto ;
Cavassani, Karen Angelica ;
Garlet, Gustavo Pompermaier ;
da Silva, Joao Santana ;
Campanelli, Ana Paula .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2011, 60 (07) :965-974
[42]   Clinical presentation of immune-related colitis associated with PD-1 inhibitor monotherapy (MONO) and combination PD-1/CTLA-4 inhibitors (COMBO) in melanoma. [J].
Wang, Daniel Ying ;
Kim, Dae Won ;
Shah, Neil J. ;
Conry, Robert Martin ;
Mehta, Rutika Jitesh ;
Silk, Ann W. ;
Zhou, Alice ;
Voorhees, Amber L. ;
Mckee, Svetlana B. ;
Norrell, Jacqueline ;
Mehnert, Janice M. ;
Puzanov, Igor ;
Gibney, Geoffrey Thomas ;
Rapisuwon, Suthee ;
Eroglu, Zeynep ;
Johnson, Douglas Buckner .
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[43]   Impact of the combined timing of PD-1/PD-L1 inhibitors and chemotherapy on the outcomes in patients with refractory lung cancer [J].
Yao, W. ;
Zhao, X. ;
Gong, Y. ;
Zhang, M. ;
Zhang, L. ;
Wu, Q. ;
Wu, L. ;
Fan, Z. ;
Yan, X. ;
Jiao, S. .
ESMO OPEN, 2021, 6 (02)
[44]   Development and validation of a nomogram to predicting the efficacy of PD-1/PD-L1 inhibitors in patients with nasopharyngeal carcinoma [J].
Chen, Yao ;
Chen, Dubo ;
Wang, Ruizhi ;
Xie, Shuhua ;
Wang, Xueping ;
Huang, Hao .
CLINICAL & TRANSLATIONAL ONCOLOGY, 2024, 26 (10) :2601-2607
[45]   Clinical Outcomes of Platinum-ineligible Patients with Advanced Urothelial Carcinoma Treated With First-line PD1/L1 Inhibitors [J].
Pond, Gregory R. ;
Agarwal, Archana ;
Ornstein, Moshe ;
Garcia, Jorge ;
Gupta, Ruby ;
Grivas, Petros ;
Drakaki, Alexandra ;
Lee, Jae-Lyun ;
Kanesvaran, Ravindran ;
Di Lorenzo, Giuseppe ;
Verolino, Pasquale ;
Barata, Pedro ;
Bilen, Mehmet A. ;
Hussain, Syed A. ;
Curran, Catherine ;
Sonpavde, Guru .
CLINICAL GENITOURINARY CANCER, 2021, 19 (05) :425-433
[46]   The efficacy of cetuximab plus PD-1 inhibitors as salvage therapy in PD-1 refractory patients with recurrent or metastatic head and neck squamous cell carcinoma [J].
Hui, Rongrong ;
Liu, Xiulan ;
Fan, Zongyu ;
Ji, Honghai ;
Wei, Dongliang ;
Ren, Guoxin .
JOURNAL OF CANCER, 2024, 15 (06) :1668-1674
[47]   Re: Prognostic Value of PD-1 and PD-L1 Expression in Patients with High Grade Upper Tract Urothelial Carcinoma [J].
Miyama, Yu ;
Miyakawa, Jimpei ;
Morikawa, Teppei .
JOURNAL OF UROLOGY, 2018, 199 (05) :1353-1353
[48]   Effect of proton pump inhibitors on the clinical outcomes of PD-1/PD-L1 inhibitor in solid cancer patients [J].
Wu, Bing ;
Sun, Congcong ;
Sun, Xiaoqin ;
Li, Xue .
MEDICINE, 2022, 101 (36) :E30532
[49]   Pre-treated anti-PD-1 refractory Merkel cell carcinoma successfully treated with the combination of PD-1/PD-L1 axis inhibitors and TVEC: a report of two cases [J].
Knackstedt, R. ;
Sussman, T. A. ;
McCahon, L. ;
Song, J. -M. ;
Funchain, P. ;
Gastman, B. .
ANNALS OF ONCOLOGY, 2019, 30 (08) :1399-1400
[50]   Overshadowed prospect of programmed cell death protein-1 (PD-1) inhibitor as monotherapy for patients with advanced hepatocellular carcinoma [J].
Yao, Xu ;
Wang, Lei ;
Gao, Jianjun .
BIOSCIENCE TRENDS, 2019, 13 (03) :282-283
12345